JB Chem gets USFDA nod for Fluconazole tablets

 According to a release issued by JB Chemicals and Pharmaceuticals to the BSE today, the approval is to manufacture and market Fluconazole tablets in the US market.

 "Fluconazole, an anti-fungal drug, is prescribed for the treatment of vaginal candidiasis, oropharyngeal and oesophageal candidiasis, cryptococcal meningitis, and prophylactic treatment of patients with bone marrow transplantation," the release added.

 "We are excited about the USFDA approval, which will further strengthen our expanding product portfolio in the US," J B Mody, chairman and managing director of JB Chemicals and Pharmaceuticals, said.